

# World Journal of *Surgical Procedures*

*World J Surg Proced* 2012 April 28; 2(2): 5-15



## Editorial Board

2011-2015

The *World Journal of Surgical Procedures* Editorial Board consists of 106 members, representing a team of worldwide experts in surgical procedures. They are from 23 countries, including Australia (1), Austria (2), Brazil (1), Canada (1), China (7), Germany (4), Greece (3), Hungary (1), India (3), Iran (2), Israel (3), Italy (10), Japan (11), Nigeria (1), Pakistan (1), Saudi Arabia (1), South Korea (3), Spain (5), Switzerland (1), Thailand (1), Turkey (3), United Kingdom (7), and United States (33).

### EDITOR-IN-CHIEF

Massimo Chello, *Rome*  
Feng Wu, *Oxford*

### GUEST EDITORIAL BOARD MEMBERS

Chiung-Nien Chen, *Taipei*

### MEMBERS OF THE EDITORIAL BOARD



**Australia**

Savio George Barreto, *Adelaide*



**Austria**

Ojan Assadian, *Vienna*  
Herwig R Cerwenka, *Graz*



**Brazil**

Djalma José Fagundes, *São Paulo*



**Canada**

Tatsuya Kin, *Edmonton*



**China**

Yong An, *Chongqing*  
Andrew Burd, *Hong Kong*  
De-Liang Fu, *Shanghai*  
Lan Huang, *Chongqing*  
Simon Siu-Man Ng, *Hong Kong*  
Qiang Wang, *Shanghai*



**Germany**

Alexander E Handschin, *Braunschweig*  
Tobias Keck, *Nürnberg*  
Matthias W Laschke, *Homburg/Saar*  
Wolfgang Vanscheidt, *Freiburg i*



**Greece**

Giannoukas D Athanasios, *Larissa*  
Dimitrios Karnabatidis, *Patras*  
Aristeidis Stavroulopoulos, *Athens*



**Hungary**

Péter Örs Horváth, *Pécs*



**India**

Nilakantan Ananthakrishnan, *Pondicherry*  
Suguna Lonchin, *Chennai*  
Muthukumaran Rangarajan, *Coimbatore*



**Iran**

Mehrdad Mohammadpour, *Tehran*  
Seyed Reza Mousavi, *Tehran*



**Israel**

Haim Gutman, *Tikva*  
Yoav Mintz, *Jerusalem*  
Solly Mizrahi, *Beersheva*



**Italy**

Franco Bassetto, *Padova*  
Fausto Catena, *Bologna*  
Luigi D'Ambra, *La Spezia*  
Giuseppe Galloro, *Naples*  
Giacomo Pata, *Brescia*  
Marcello Picchio, *Latina*  
Giuseppe Piccinni, *Bari*  
Raffaele Russo, *Naples*  
Pierpaolo Sileri, *Rome*



**Japan**

Hiroki Akamatsu, *Osaka*  
Akihiro Cho, *Chiba*  
Yoshiki Hirooka, *Nagoya City*  
Yasuhiro Ito, *Kobe*  
Daisuke Morioka, *Yokohama*  
Nobuhiro Ohkohchi, *Tsukuba*  
Norio Shiraishi, *Oita*  
Kuniya Tanaka, *Yokohama*  
Atsushi Watanabe, *Sapporo*  
Toshiaki Watanabe, *Tokyo*  
Yo-ichi Yamashita, *Hiroshima*



**Nigeria**

Christopher Olusanjo Bode, *Lagos*



**Pakistan**

Drshamim Muhammad Shamim, *Karachi*



**Saudi Arabia**

Abdul-Wahed Meshikhes, *Qatif*

**South Korea**

Sung-Hyuk Choi, *Seoul*  
 In Ja Park, *Seoul*  
 Sung-Soo Park, *Seoul*

**Spain**

Maria Angeles Aller, *Vallehermoso*  
 Manuel Giner, *Madrid*  
 David Martinez-Ramos, *Castellon*  
 Juan Viñas Salas, *Leida*  
 Eduardo M Targarona, *Barcelona*

**Switzerland**

Pascal Gervaz, *Geneva*

**Thailand**

Varut Lohsiriwat, *Bangkok*

**Turkey**

Ali Doğan Bozdağ, *Aydin*  
 Mehmet Fatih Can, *Ankara*  
 Cem Kaan Parsak, *Adana*

**United Kingdom**

Basil Jaser Ammori, *Manchester*  
 Sanjoy Basu, *Ashford*  
 Gianpiero Gravante, *Leicester*  
 James Kirkby-Bott, *London*  
 Kefah Mokbel, *London*  
 Mikael Hans Sodergren, *London*  
 Emmanouil Zacharakis, *London*

**United States**

Amir Abolhoda, *Orange*  
 Ronald Scott Chamberlain, *Livingston*  
 Steven D Chang, *Stanford*  
 Yi-Jen Chen, *Duarte*  
 Danny Chu, *Houston*

Gaetano Ciancio, *Florida*  
 John V Conte, *Maryland*  
 Ruy J Cruz Jr, *Pittsburgh*  
 Steven C Cunningham, *Baltimore*  
 Konstantinos P Economopoulos, *Boston*  
 Thomas Joseph Fahey, *New York*  
 Eric Joseph Grossman, *Chicago*  
 Andrew A Gumbs, *Berkeley Heights*  
 Steven N Hochwald, *Gainesville*  
 Sergio Huerta, *Texas*  
 Alexander Iribarne, *New York*  
 David M Kahn, *Pala Alto*  
 Kanav Kahol, *Arizona*  
 Randeep Singh Kashyap, *New York*  
 Chung H Kau, *Vestavia Hills*  
 Julian Emil Losanoff, *Las Vegas*  
 Timothy Michael Pawlik, *Baltimore*  
 G Portillo-Ramila, *San Antonio Texas*  
 Jonathan C Samuel, *Chapel Hill*  
 Herrick J Siegel, *Birmingham*  
 Brad Elliot Snyder, *Houston*  
 Bill Tawil, *Los Angeles*  
 James Fallon Thornton, *Dallas*  
 Jiping Wang, *Boston*  
 Hongzhi Xu, *Boston*  
 Hua Yang, *Ann Arbor*  
 Rasa Zarnegar, *San Francisco*



# World Journal of Surgical Procedures

## Contents

Bimonthly Volume 2 Number 2 April 28, 2012

### TOPIC HIGHLIGHT

5

Molecular biology techniques for the surgeon

*Kowdley G, Srikantan S, Abdelmohsen K, Gorospe M, Khan J*

**ACKNOWLEDGMENTS** I Acknowledgments to reviewers of *World Journal of Surgical Procedures*

**APPENDIX** I Meetings  
I-V Instructions to authors

**ABOUT COVER** Editorial Board Member of *World Journal of Surgical Procedures*, Steven C Cunningham, MD, Department of Surgery, Saint Agnes Hospital, 900 Caton Avenue, Mailbox 207, Baltimore, MD 21229, United States

**AIM AND SCOPE** *World Journal of Surgical Procedures (World J Surg Proced, WJSP, online ISSN 2219-2832, DOI: 10.5412)* is a bimonthly peer-reviewed, online, open-access, journal supported by an editorial board consisting of 106 experts in surgical procedures from 23 countries.

*WJSP* aims to report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of surgical procedures. *WJSP* covers ambulatory, cardiovascular, digestive system, endocrine, obstetrics, neuro-, ophthalmologic, oral, otorhinolaryngologic, orthopedic, reconstructive, thoracic, urogenital, computer-assisted, elective and minimally invasive surgical procedures, specifically including ablation techniques, anastomosis, assisted circulation, bariatric surgery, biopsy, body modification, non-therapeutic, curettage, debridement, decompression, deep brain stimulation, device removal, dissection, drainage, electrosurgery, extracorporeal circulation, hemostasis, intraoperative care, laparotomy, ligation, lymph node excision, mastectomy, microsurgery, monitoring, intraoperative, ostomy, paracentesis, pelvic exenteration, perioperative care, postoperative care, preoperative care, prosthesis implantation, reoperation, second-look surgery, splenectomy, suture techniques, symphysiotomy, tissue and organ harvesting, transplantation, diagnostic imaging, endoscopy, traditional medicine, integrated Chinese and Western medicine, evidence-based medicine and epidemiology.

**FLYLEAF** I-III Editorial Board

**EDITORS FOR THIS ISSUE** Responsible Assistant Editor: *Xiao-Cui Yang* Responsible Science Editor: *Xin-Zhen Huang*  
Responsible Electronic Editor: *Jun-Yao Li* Proofing Editorial Office Director: *Jin-Lei Wang*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

**NAME OF JOURNAL**  
*World Journal of Surgical Procedures*

**ISSN**  
ISSN 2219-2832 (online)

**LAUNCH DATE**  
December 29, 2011

**FREQUENCY**  
Bimonthly

**EDITING**  
Editorial Board of *World Journal of Surgical Procedures*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893  
E-mail: [wjsp@wjgnet.com](mailto:wjsp@wjgnet.com)  
<http://www.wjgnet.com>

**EDITOR-IN-CHIEF**  
**Massimo Chello, MD, Professor**, Department  
of Cardiovascular Sciences, University Campus Bio

Medico of Rome, Via Alvaro Del Portillo 200, 00128  
Rome, Italy

**Feng Wu, MD, PhD, Professor**, Nuffield Department  
of Surgical Sciences, University of Oxford,  
Level 6, John Radcliffe Hospital, Headley Way, Ox-  
ford, OX3 9DU, United Kingdom

**EDITORIAL OFFICE**  
Jian-Xia Cheng, Director  
Jin-Lei Wang, Vice Director  
*World Journal of Surgical Procedures*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893  
E-mail: [wjsp@wjgnet.com](mailto:wjsp@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building,  
No.90 Jaffe Road, Wanchai, Hong Kong, China  
Fax: +852-31158812  
Telephone: +852-58042046

E-mail: [bpg@baishideng.com](mailto:bpg@baishideng.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
April 28, 2012

**COPYRIGHT**  
© 2012 Baishideng. Articles published by this Open-  
Access journal are distributed under the terms of the  
Creative Commons Attribution Non-commercial  
License, which permits use, distribution, and reproduc-  
tion in any medium, provided the original work is prop-  
erly cited, the use is non commercial and is otherwise in  
compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the  
viewpoints of the authors except where indicated oth-  
erwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/2219-2832/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2219-2832/g_info_20100722180909.htm)

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esp/>

Steven C Cunningham, MD, Series Editor

## Molecular biology techniques for the surgeon

Gopal Kowdley, Subramanya Srikantan, Kotb Abdelmohsen, Myriam Gorospe, Javeed Khan

Gopal Kowdley, Javeed Khan, Department of Surgery, St Agnes Hospital, Baltimore, MD 21229, United States  
Gopal Kowdley, Subramanya Srikantan, Kotb Abdelmohsen, Myriam Gorospe, Laboratory of Molecular Biology and Immunology, National Institute on Aging, NIH, Baltimore, MD 21224, United States

Author contributions: All authors contributed equally to this review.

Supported by The National Institute on Aging-Intramural Research Program, National Institutes of Health

Correspondence to: Gopal Kowdley, MD, PhD, General Surgeon, Associate Program Director, Department of Surgery, St Agnes Hospital, 900 S. Caton Ave, Baltimore, MD 21229, United States. [gkowdley@gmail.com](mailto:gkowdley@gmail.com)

Telephone: +1-443-9283932 Fax: +1-410-9514007

Received: October 10, 2011 Revised: March 20, 2012

Accepted: March 27, 2012

Published online: April 28, 2012

### Abstract

New technologies are constantly being introduced into the medical and surgical fields. These technologies come in the form of newer medicines, imaging methods and prognostic tools, among others, and allow clinicians to make more rational and informed decisions on the care of their patients. Many of these technologies utilize advanced techniques which are at the forefront of many research fields and represent a transition of bench advances into the clinical realm. This review will highlight four technologies that are at the forefront in the treatment of oncology patients treated by surgeons on a daily basis. Circulating tumor cells, microarray analysis, proteomic studies and rapid sequencing technologies will be highlighted. These technologies will be reviewed and their potential use in the care of surgical patients will be discussed.

© 2012 Baishideng. All rights reserved.

**Key words:** Methods; Molecular diagnostic techniques; Medical oncology; General surgery MT

**Peer reviewers:** Juan Viñas Salas, Professor of Surgery, Department of Surgery, Arnau de Vilanova University Hospital, Alcalde Rovira Roure 80, 25198 Lleida, Spain; Konstantinos P Economopoulos, MD, Research Fellow in Surgery, Department of General Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA 02114, United States

Kowdley G, Srikantan S, Abdelmohsen K, Gorospe M, Khan J. Molecular biology techniques for the surgeon. *World J Surg Proced* 2012; 2(2): 5-15 Available from: URL: <http://www.wjgnet.com/2219-2832/full/v2/i2/5.htm> DOI: <http://dx.doi.org/10.5412/wjsp.v2.i2.5>

### INTRODUCTION

The pace of technological advancement in medicine has been substantial. With each advance, not only in the field of biology but in other fields such as information technology, image processing, manufacturing methods and data processing, many aspects of medicine are experiencing great change and our ability to study processes in great detail is expanding vastly. These techniques will become more commonplace and will become a greater part of a surgeon's daily practice, especially in our cancer patients.

This review will highlight specific techniques in four major areas of study that have been advancing to the forefront of efforts in the treatment of surgical patients with malignancies. Some of these techniques have been known for some time; however, with advancement of related fields, the real-time practical utilization of these techniques in the care of our patients has escalated in recent years.

We will review the techniques associated with the identification and characterization of circulating tumor cells, the genes expressed in cancer cells (microarray analysis, rapid sequencing methods and proteomics). These methods, along with their applications in the field of oncology, will be highlighted in this paper.

## CIRCULATING TUMOR CELLS

Circulating tumor cells (CTC) and disseminated tumor cells (tumor cells in the bone marrow) are becoming more important in the study of patients with cancers as distant metastasis remain a major cause of cancer related deaths<sup>[1,2]</sup>. The hypothesis that these cells are released into the circulation and may be responsible for the dissemination of cancer cells has been suggested for over a century; however, only recently have we been able to detect them in a commercially viable fashion and have begun to understand their significance in disease<sup>[2,3]</sup>. The detection of these tumor cells in the clinical treatment of cancer patients is becoming important as many patients thought to have localized disease are actually found to have distant disease on relapse<sup>[2,4-7]</sup>. As our ability to measure these cells in the circulation from cancer patients increases, the idea of metastatic spread being a late event in tumor development is being questioned.

### Enrichment

CTCs exist in the blood and the bone marrow at very low levels (one cell per  $10^5$ - $10^7$  cells)<sup>[1,2,5]</sup> and an enrichment step is often utilized prior to actual detection of these cells to make the detection of these cells more efficient. Three main methods of enrichment are based on filtration, density gradients and immunomagnetic enrichment<sup>[2,5]</sup>. Density and filtration methods work on a size basis. Immunomagnetic methods rely on surface markers present on tumor cells that are not present on background cells. Once the samples are enriched, CTCs can be identified and studied.

Several methods utilize size differences between cells to enrich the sample. Isolation by size of epithelial tumor cells is a size-based filtration method. This method utilizes 8  $\mu$ m pores which allow separation of small leukocytes from larger epithelial cells. This method allows the detection of one tumor cell from a 1 mL sample of blood<sup>[8]</sup>. Micro electro-mechanical system is another method that has been developed that takes advantage of size differences between CTCs and other blood cells. This method provides a high-efficiency membrane based system that allows for high throughput of samples<sup>[9]</sup>. The advantages and disadvantages of these methods have been summarized in other reviews<sup>[5,10]</sup>; briefly, size differences are not absolute for cell lines and thus the sensitivity and specificity of these techniques are low.

CTCs and mononuclear cells have different densities from red blood cells and granulocytes. Density gradient methods using Ficoll-Hypaque make use of this property to enrich CTCs. Often CTCs are lost in the process and the use of these chemicals has been associated with toxicity to cells. This method is also considered to have low specificity and requires a lot of processing time<sup>[11,12]</sup>. A commercially available method, Oncoquick (Greiner Bio-One, Germany), utilizes a membrane layer in the process to minimize cross contamination and saves some time for processing of samples when compared to the Ficoll method<sup>[12]</sup>. Other technologies exist as well

and utilize a negative selection method<sup>[13,14]</sup>.

Immunomagnetic enrichment is another major technique of enrichment. In this process, magnetic beads are coated with antibodies that are expressed on CTCs. Samples are then mixed with the beads to allow binding of cells with the given markers. The CTCs once bound to the beads are separated from the unbound fraction (background) by use of a magnetic field, thus positively selecting for CTCs. The antibodies employed are usually against epithelial markers or tumor specific antigens [e.g., cytokeratins (CKs), epithelial cell adhesion molecule (EpcAM), carcinoembryonic antigen, the human epidermal growth factor receptor 2]. Negative selection methods in which antibodies against the background cells (leukocytes, megakaryocytes) are used may also be employed and have the advantage of not disturbing the cells of interest<sup>[15-17]</sup>. These methods require no cell lysis, are less toxic to the cells, and allow for specific identification of CTCs when compared to size methods described previously. Commercially available technologies exist that make use of these immunomagnetic methods and employ semi automated methods for detection of CTCs. Veridex (Johnson and Johnson, Raritan NJ) and the CellSearch<sup>TM</sup> system are two systems that are available<sup>[11,18]</sup>. The major drawback to any of these immunological methods is that they rely on markers that are not absolute in distinguishing tumor cells from background. In addition, there is significant variation in expression of markers within tumors themselves and at different stages of tumor growth<sup>[5,11,19]</sup>. False positive and false negative selection has been identified in both methods, making the detection of all CTCs not possible with current enrichment methods.

### Identification

Once CTCs are isolated, they are further characterized based on their nucleic acid expression or protein expression. These methods can be broadly characterized into polymerase chain reaction (PCR)-based analysis and cytometric analysis. Each of these techniques, as with all methods, has their pros and cons and is summarized well in another review<sup>[5]</sup>.

PCR-based techniques are very sensitive when compared to immunocytochemistry methods and have been used in the clinical setting<sup>[20,21]</sup>. These methods achieve their specificity by the design of oligonucleotide primers targeted against genes of interest. Reverse transcription (RT)-PCR is generally the method employed for amplifying mRNAs of interest<sup>[21-23]</sup>. Multiplex RT-PCR methods have been developed to increase the sensitivity and specificity of this method, also allowing the screening of multiple markers at one time, and are discussed elsewhere in this paper.

Cytometric methods isolate and count cancer cells. This is performed most widely by the use of monoclonal fluorescently labeled antibodies directed against different antigens with the most common ones again being CKs and EpcAM<sup>[2,5]</sup>. As cells are not lysed, the integrity of the cells is maintained and this allows further char-

acterization of these cells, including their size and their nucleus-to-cytoplasm relationship. The major limitation of this technique is one that is similar to all methods that use antibody-based techniques, specificity of target proteins, heterogeneity of tumors and protein expression. Once cells are coated with the antibody, they are scanned and analyzed using criteria developed for their evaluation<sup>[2,24,25]</sup>.

Fiber-optic array scanning technology is a scanning technology that uses a large field of view for detection of bound antibody. This technology allows the analysis of large volumes of samples without a purification step and allows for the scanning of up to 300 000 cells per second, about 500 times faster than conventional automated digital microscopy<sup>[26,27]</sup>. This technology is being used in clinical practice at this time<sup>[28]</sup>. Other automated systems have been developed and are described elsewhere<sup>[29-34]</sup>, including CellSearch™.

Other technologies make use of chips that are coated with antibodies of interest. Blood is pumped through the chip and cells are captured. This method was shown to have a significantly improved sensitivity when compared to other techniques, with identification of CTCs in 99% of samples from multiple tumors<sup>[35,36]</sup>. These cells may be further analyzed for function of trapped proteins, as has been shown for telomerase activity recently<sup>[37]</sup>. More detailed analysis of arrays will be covered in subsequent sections.

### Clinical applications of CTCs

In the United States, breast cancer is the most common non-skin cancer and the second leading cause of the cancer-related death in women. Despite advances in screening programs and new chemotherapy agents, 6%-10% of women present with metastatic disease. The 5-year overall survival rate among such patients rarely exceeds 20%<sup>[38]</sup>. Cristofanilli *et al.*<sup>[4]</sup> have shown that the presence of high CTC number ( $\geq 5/7.5$  mL of whole blood) is associated with shorter progression-free and overall survival in the metastatic setting and their continued presence following the initiation of a therapy predicts impaired therapeutic responses and overall survival in breast cancer patients. Botteri *et al.*<sup>[38]</sup> showed that the number of CTCs at baseline and their perpetual changes at different follow-up points is a strong independent predictor of progression-free-survival (PFS) but not overall survival (OS). Currently, CTC assessment has been approved by the Food and Drug Administration (FDA) as a prognostic factor to segregate the patients with metastatic breast cancers into favorable or unfavorable groups and may represent a robust predictive factor in this metastatic population<sup>[36,39]</sup>.

Colorectal cancer (CRC) is the second leading cause of overall cancer death in the United States<sup>[40,41]</sup>. CTCs can serve as both prognostic and predictive agents for patients with metastatic CRC. In a large prospective multicenter trial of 413 patients with metastatic CRC commencing first, second or third line therapy, patients with

baseline CTC number  $\geq 3$  had significantly worse median PFS (4.4 mo *vs* 7.8 mo,  $P = 0.004$ ) and OS (9.4 mo *vs* 20.6 mo,  $P < 0.0001$ ) compared with patients with  $< 3$  CTCs<sup>[40]</sup>. The baseline CTC number was an important predictive factor even within specific patient subgroups defined by treatment or patient characteristics.

In the light of the available evidence, the FDA has approved CTC analysis by Cell Search™ in metastatic breast, colorectal and prostate cancer patients as an indicator of prognosis<sup>[41]</sup>. There is scarcity of information regarding CTCs in many other tumors, including melanoma, head/neck cancers, biliary and pancreatic cancers. Preliminary results are encouraging but need further study.


## MICROARRAYS AND USE IN CANCER

### OVERVIEW

#### Gene expression analysis using microarrays

In the nucleus of virtually all cells in the body is a full set of chromosomes, which contain tens of thousands of genes, the DNA genetic code. However, in each cell type, only a fraction of these genes is “expressed”, that is, used for the synthesis of protein. The specific set of proteins produced in each cell confers unique properties to the cell. The term “gene expression” describes a process whereby the information contained in the genes in the form of DNA is used to synthesize (transcribe) a messenger (m) RNA molecule that will be transported to the cytoplasm and used as a temporary template for the synthesis of proteins (translation) that will perform the functions of the cell. Studying the levels and types of mRNAs expressed in the cell provides indirect information about the proteins expressed in that cell. As the cellular needs change to adapt to internal conditions and external stimuli, so do the patterns (type and amount) of expressed mRNAs. The maintenance of adequate gene expression patterns is important for the preservation of cellular homeostasis. Disruptions in the levels or types of expressed mRNAs underlie many disease processes, including cancer.

Traditional technologies to study gene expression only allowed scientists to study a handful of expressed mRNAs at a time. In the mid 1990s, the microarray technology emerged as a new tool that began to allow scientists to survey many mRNAs at the same time in a quick, inexpensive and efficient manner. This major methodological advance permitted scientists to explore the patterns of expressed genes during physiological processes (such as development and normal tissue function) and in pathological states, such as cancer and many other diseases<sup>[42-44]</sup>. The microarray technology is based on the ability of a given mRNA molecule to bind (or “hybridize”) specifically to a DNA template of complementary sequence (Figure 1). Microarrays contain thousands of DNA sequences immobilized at fixed spots on small, solid supports which are typically glass microscope slides, but can also be silicon chips or ny-



**Figure 1 Hybridization of the target to the probe.** Probes are fixed to the matrix and labeled targets are allowed to hybridize with the probes (source: public domain).

lon or nitrocellulose membranes. The DNA sequences themselves are typically oligonucleotides (single-stranded DNA sequences of 5-50 nucleotides) but can also be longer DNA molecules.

### Types of microarray analysis

There are three basic types of DNA microarrays, each yielding different types of information. Traditional microarrays provide information about the patterns of expressed mRNAs, while new applications of microarrays make available information on changes in the composition of DNA within the samples analyzed.

**Microarray analysis of changes in the levels of expressed mRNAs:** Also known as “gene expression microarrays”, this technology provides useful information on the types and quantities of mRNAs expressed in a given sample<sup>[45]</sup>. In these microarrays, the immobilized DNAs are typically oligonucleotides and the samples used in hybridization are prepared from mRNA extracted from cells or tissues. The mRNA is then reverse-transcribed to yield complementary DNA (cDNA) subsets which are labeled with radioactivity or fluorescence. If the samples are derived from healthy tissue and cancer tissue from a patient, for example, after hybridization and signal detection and analysis, the microarray can uncover specific sets of genes differentially expressed between the two tissues. This information can then be used to decide on the appropriate therapeutic regimen for the patient. This information can also be used in the rational design of effective drugs.

**Microarray analysis to uncover genomic gains and losses:** Comparative genomic hybridization (CGH) microarrays are used to study large genomic gains and losses, as well as to identify changes in the number of copies of a particular gene involved in a disease state<sup>[46]</sup>. In microarray CGH, each spot of target DNA in the array has a known chromosomal location and the samples tested are large pieces of genomic DNA. For example, the comparison can be made between labeled genomic DNA prepared from a normal tissue with labeled ge-

nomeric DNA prepared from a cancer tissue. This type of analysis is particularly useful in the study of diseases in which certain genes or groups of genes might be deleted; gross deletions occur frequently in cancer, affecting regions that encode tumor suppressor or DNA repair genes. Regions of selective gene amplification have also been reported in cancers, often affecting oncogenes and genes involved in DNA replication. The microarray CGH analysis can reveal these regions of lost or gained DNA and thereby uncover specific genes increasing or decreasing in the disease<sup>[47,48]</sup>.

**Microarray detection of DNA mutations:** Although in cancer many more genes are altered in their abundance than are mutated<sup>[49]</sup>, in some cases researchers can use microarrays to detect small mutations or polymorphisms in the sequence of a gene. In this type of analysis, the DNA spots immobilized on the array may differ from one another by only one nucleotide or a few specific nucleotides and the probe used is genomic DNA from the individual. These microarrays are frequently used to identify single nucleotide polymorphisms (SNPs), small variations in gene sequence that occur in the human population. This microarray approach is particularly useful in the detection of specific cancer types and other diseases (or the susceptibility to diseases) associated with a given SNP pattern<sup>[50]</sup>.

### Use of microarrays in cancer diagnosis, prognosis and therapy

Microarrays are particularly useful for studying a large number of genes quickly. They can measure mRNA expression levels for thousands of genes at once and can rapidly identify large or small mutations on a global genomic scale. Microarrays have been extremely valuable in identifying the genes implicated in cancer and other diseases. For example, microarray comparisons of “healthy” (or “control”) tissue from an individual, with cancer tissue from the same individual (for example, from a biopsy or intra-operative sample) have provided valuable information about the specific changes that have occurred in that particular cancer, specifically alterations in the abundance of expressed mRNAs and any gross deletions or amplifications. This information has been useful in guiding specific aspects of cancer therapy and in helping with its prognosis<sup>[51-53]</sup>. Microarrays have also been used to distinguish between specific types of cancer and to provide clues on the most effective treatment regimens<sup>[54,55]</sup>. The use of microarrays to compare one individual population to another has been used to identify specific SNPs associated with the likely development of certain diseases and thus have helped with prevention and monitoring plans.

Studies in the clinical setting are beginning to show promise for identifying patients with a poor prognosis based on differential gene expression profiles. In Ntzani *et al.*<sup>[51]</sup>, receiver operating curves for various cancers were reviewed and a sensitivity and specificity for predicting death in patients with breast cancer were 91%

and 73%, respectively. In this analysis, only studies that included more than 500 genes were used. In a study of Duke's C colon cancer<sup>[52]</sup> patients, a total of 236 sequences from 218 genes were noted to be differentially expressed in patients with or without recurrence in 5 years. The expression of K-ras was not predictive of outcome in these patients; however, the expression of *RHOA*, a ras analogue, was an excellent predictor of recurrence in these patients. In another study of patients with colorectal cancer, the predictive value of outcome using gene array data was significantly better than traditional clinical staging methodologies<sup>[53]</sup>. In a recent study of breast cancer patients, the over-expression of genes *ANLN*, *KIF2C* and the under-expression of *MAPT* gene strongly correlated with poor outcomes in breast cancer patients<sup>[55]</sup>. A recent paper comparing gene expression using microarray technology compared profiles between patients that had normal colorectal mucosa with patients with adenomas and adenocarcinomas<sup>[56]</sup>, identified a novel gene locus that is activated very early in the process of neoplasia and may be used in the future as a novel tissue or plasma marker for disease.

At present, microarray analysis is still labor-intensive and requires a minimum of 48 h to collect samples, isolate and process RNA, prepare labeled probes, hybridize microarrays, analyze microarray signals and compare samples to samples and to existing databases. For this reason, microarrays are useful for mid- to long-term planning of health care decisions. For decisions that need to be made in a shorter time-frame (e.g., intraoperatively), the technology will still require a significant amount of automatization and streamlining in order to be practical in such settings. While individualized medicine is still in the early stages, however, based on the concept of microarray analysis, hand-held devices to diagnose disease and to personalize therapy for an individual patient will likely be a reality for physicians in the not too distant future.

## PROTEOMICS AND CANCER

As highlighted above, the study of cancer by gene arrays has been widely used to detect changes in gene expression. However, gene arrays do not always reflect changes in protein abundance. Furthermore, posttranslational changes, such as phosphorylation, acetylation, ubiquitinylation, protein interactions and subcellular localization, cannot be resolved by gene arrays. These changes are very important for protein stability and activity and may determine cell fate and thus protein studies (proteomics) are essential to uncover these modifications. There are several proteomic techniques that help scientists to understand and functionally relate protein changes and cell networking. The techniques described below can be used to analyze a wide range of samples, including normal tissue samples as well as solid tumors such as lung, breast, colon and liver. We will cover the techniques first and then point out current applications

of the technology in the clinical setting.


### Mass spectrometry

This technique determines the mass of charged molecules in tissue samples and is used for protein identification. Mass spectrometry (MS) can be used to study the proteome of mouse solid tumor lysates with similar efficiency as cell culture models and in amounts compatible with biopsies<sup>[57]</sup>. Cancer prediction, early detection, response to therapy, evaluation and recurrence have been studied by MS among several solid tumors, including lung and gastrointestinal malignancies<sup>[58-64]</sup>. In addition, MS can be used to determine the abundance of different proteins in cancer tissues compared to normal tissues using two-dimensional gel electrophoresis<sup>[65]</sup>. This technique of electrophoresis begins with the two-dimensional separation of proteins: the first dimension separates proteins according to their charges and is known as isoelectric focusing, while the second dimension separates proteins according to their molecular weights by sodium dodecyl sulfate polyacrylamide gel electrophoresis. This method is quantitative and can resolve hundreds, possibly thousands, of proteins that are differentially expressed. MS analysis is indeed of high impact in cancer research since it can provide essential information such as protein identity, quantity and its posttranslational modifications such as phosphorylation.

Such techniques are being used to characterize the heterogeneity of tumor cells from a single cancer type. Using these techniques, over 1000 lung tissue samples have been analyzed and the protein PGK1 has been shown to be an excellent predictor of survival in patients with stage I lung cancer<sup>[58]</sup>. In another study of 174 non small cell lung cancer tumors with normal controls, it was shown that over 25 proteins were differentially expressed between the two lines. Blood from healthy individuals has been studied against patients with a tumor and a protein profile has been identified with a 73% sensitivity and 90% specificity for detection of head and neck cancers<sup>[58,64]</sup>. Similar protein profiles between healthy and patients with ovarian and prostate cancers have been identified<sup>[64]</sup>. These observations highlight the importance of these techniques as they apply to prognosis and detection in cancer cell lines and may come into clinical practice in the foreseeable future, necessitating familiarity with such techniques for surgeons.

### Stable isotope labeling by/with amino acids in cell culture

This technology also utilizes MS to globally determine protein abundance in cultured cells. In this method, growing cells are labeled by light medium with normal arginine (Arg-0) or heavy medium with arginine 6 (Arg-6). Arg-0 and Arg-6 metabolically incorporate into proteins, resulting in a shift in the mass of the corresponding peptides that can be detected by MS (Figure 2). Since its development almost ten years ago, stable isotope labeling by/with amino acids in cell culture (SILAC) has been used in cultured cells but not tissues or body fluid



**Figure 2** SILAC-heavy and light arginine is placed in growth medium for cultured cells. Incorporation of the light and heavy arginine results in a mass shift of corresponding peptides. Mass spectroscopy is then utilized to detect the ratios of the peak intensities. The ratio reflects the relative protein abundance in the two samples. Arg: Arginine. (Source: public domain).

analysis; however, scientists are currently expanding this method for use in human cancer tissues and recently developed a technique known as Super-SILAC mix<sup>[66]</sup>. Although this strategy is still in its infancy, it extends SILAC-based quantitative proteomics to the study of proteins in cancer tissues. It can be used for the early detection of cancers<sup>[67]</sup> through the identification of potential biomarkers<sup>[68]</sup>, pharmacological targets<sup>[69]</sup>, molecular networks<sup>[70]</sup> and post-translational modifications<sup>[71,72]</sup>.

Esophageal cancer, often insidious in presentation and unresectable at detection, has been studied with this technique to identify specific protein profiles that differ between normal esophageal epithelial cells and those of esophageal carcinoma cells. In one study, a total of 441 proteins were studied and over 120 proteins were identified as being > 2 fold up regulated in cancer cells. Such techniques potentially allow for the early detection of patients with esophageal cancer, allowing surgical therapy to be of benefit to a larger group of patients<sup>[68]</sup>.

### **Western blotting, immunohistochemistry and enzyme-linked immunosorbent assay**

Western blotting (WB) is widely used and based on antibody technology. Protein sequence, molecular weight and post-translational modification can be studied by WB. Lysates from all types of tissue, including solid tumors, can be studied by WB to investigate aspects of protein characteristics, including abundance, stability and posttranslational modification. In cancer research, large numbers of proteins can be investigated using this technology in the form of protein microarrays, discussed elsewhere in this review<sup>[73,74]</sup>.

Immunohistochemistry (IHC) also enables researchers to determine protein abundance, posttranslational modification and, more importantly, direct assessment of its subcellular localization. IHC is the most common way to visualize protein-antibody interaction and is based upon fluorescence technology. This method has clearly advanced our knowledge of cells since tissues can be organized and stained in an array format known as tissue

arrays. IHC is becoming widely used since it enables researchers to screen the expression of certain proteins in a large number of tissues (normal and cancer) in a short time and in a cost-effective manner.

The enzyme-linked immunosorbent assay (ELISA) technique is used to detect proteins from samples of different origin, from intact tissue or cell lysates, and from fluids such as blood. ELISA can detect protein abundance and also posttranslational modification to proteins such as phosphorylation. ELISA is quick, simple and amenable to studying large numbers of samples and is used as a diagnostic method to detect tumor markers for earlier detection of cancers<sup>[75,76]</sup>.

The methods summarized above have a great impact on our understanding and ongoing investigation in tumor proteomics. We believe that these techniques will develop further, making them more efficient, accurate, fast and cost-effective.

## **RAPID SEQUENCING TECHNIQUES**

### **Use of high-throughput sequencing technology in biology and medicine**

The completion of sequencing of the human genome has opened a floodgate of opportunities to understand biological processes, variations among individuals and between normal and disease states. Many research groups are now investigating global changes in chromosomal DNA or their transcribed RNA. The need for fast and accurate sequencing methods to carry out these studies has led to the development of many innovative sequencing platforms, collectively known as high-throughput sequencing (HTS) technology. Thanks to this technology, we now have datasets available on various aspects of cellular biology, including genome, transcriptome, epigenome and interactome, leading to a better understanding of biological processes<sup>[77]</sup>. Here, we discuss some of the applications of HTS approaches and their use in understanding diseases. This will be a fairly detailed look at the techniques and several examples of current clinical use will be highlighted. These methods are in their infancy and direct application to the clinical setting is only beginning to be realized.

**Methodology:** Distinct chemistry and technology are involved in different HTS platforms. Typically, all of the platforms depend on parallel sequencing on multiple short DNA fragments (typically 50-300 bases) generated from genomic DNA or from cDNA. These sequence reads are then aligned to the available genome databases and processed to get relevant information. The data generated from such experiments are enormous and can serve as a source for unending analysis to get different kinds of information. Upon initial publication, the data is made available in public databases for other scientists to use in their analysis, which ultimately enriches our knowledge of biological processes.

**Different uses of HTS technology**

**Genome analysis:** Scientists studying human genetics ultimately aim to map every genetic variant and link them to phenotype. Many genome-wide association studies reveal that only a modest fraction of heritable risk for common diseases is explained by known genetic variants. This raises the question whether rare variants exist in individuals which could account for unexplained heritability. Recent developments in HTS have helped to address this question by sequencing whole genomes or part of the genomes to identify genetic variations that could lead to disease. For example “exome-sequencing” (sequencing of all protein coding regions) of eight normal individuals and four individuals with a rare dominantly inherited disorder, Freeman-Sheldon syndrome (FSS), led to the identification of many rare and common variants in the coding sequences. Extensive analysis of this data set revealed that *MYH3* (identified previously by a candidate gene approach) was a candidate for FSS<sup>[78]</sup>. This proof of principle analysis has been followed up by other such analysis, leading to identification of novel candidate genes for different diseases<sup>[79]</sup>. HTS has also been used to detect personalized copy-number variants and gene-fusion events which could explain individual differences in susceptibility to diseases<sup>[80]</sup>. The use of such information has the potential for identifying individual susceptibilities to various diseases and specifically cancers. This information may allow for potential screening of true at risk individuals based on their sequence specific propensities for cancer development.

**Transcriptome analysis:** HTS has opened up the doors to study the RNA transcripts generated from the chromosomal DNA in ways which were not possible using traditional sequencing methods or microarrays<sup>[81]</sup>. For example, using HTS, we not only get the qualitative and quantitative data on expression of all known protein coding RNAs (similar to that of microarray), but also that as yet unknown RNA transcripts. For example, HTS can identify the presence of unknown gene fusions<sup>[82]</sup>, RNA editing and new classes of noncoding RNAs, as well as unknown and less abundant splice variants and splice regions<sup>[83]</sup>. Combining HTS with the nuclear run-on assay has allowed scientists to monitor transcription rates, as well as to appreciate the prevalence of antisense transcription, divergent transcription and transcription extending beyond the pre-messenger RNA 3' end cleavage site<sup>[84]</sup>. As an extension of this methodology, one can also monitor the rate of mRNA degradation, as well as understand the degradation processes using HTS. These data not only enrich our knowledge of biological processes but also help us to differentiate normal and diseased states. For example, it can help in the identification of an unknown gene fusion event<sup>[82]</sup>, non-coding RNA<sup>[85]</sup>, splice variant or RNA editing that could be responsible for a given disease.

**Epigenome analysis:** Epigenetic modifications broadly

describe modifications of the basic components of chromatin, i.e., DNA and histone proteins<sup>[86]</sup>, which typically control transcription. It is now increasingly appreciated that epigenetic abnormalities play a key role in cancer and other diseases<sup>[87]</sup>. HTS coupled to techniques like bisulfate treatment (for DNA methylation status) or chromatin immunoprecipitation of modified histones are employed to understand genome-wide epigenetic differences between normal and abnormal (e.g., disease) phenotypes<sup>[88-90]</sup>. Many of the protein modifications occurred in genes responsible for pluripotency and differentiation, perhaps indicating their importance in inducing cancer in cell lines. The powerful DNase I hypersensitivity site footprinting coupled to HTS is used to define open chromatin structures which are the potential regulatory sequences<sup>[91]</sup>.

**Interactome analysis:** To understand how genes bring about a phenotype, it is important to understand the functional and physical interactions of chromosomal genes, as well as their products (RNA and protein). Investigation of these interactions is important to further our knowledge of diseases<sup>[92]</sup>. Chromatin immunoprecipitation followed by sequencing (ChIP-Seq) is the most sought-after method to identify transcription factor or transcription complex binding to chromosomes. For example, since the sites binding by RNA polymerase II (RNAPol II) usually define active transcription, ChIP-Seq of RNAPol II has been used to investigate questions such as the transcriptional state, the normal transcription starting sites, and the prevalence of aberrant or alternate transcription starts<sup>[89,93]</sup>. Combinatorial analysis of different ChIP-Seq experiments can lead to the understanding of the complex nature of chromosome organization and how it is regulated by many cellular factors. For example, Barski *et al.*<sup>[89]</sup> used ChIP-Seq analysis to generate high-resolution maps for the genome-wide distribution of histones, RNA polymerase II and CCCTC-binding factor (CTCF; the insulator binding protein) across the human genome, which revealed the complex nature of genome organization and how this affects transcription. Similarly, ChIP-Seq analysis of estrogen receptor  $\alpha$  (ER- $\alpha$ ; key component of estrogen regulated transcription) and RNA polymerase II not only revealed the binding sites of ER- $\alpha$  on human chromosomes but also showed the complexity of transcriptional states of these genes in response to estradiol and/or its antagonists<sup>[94,95]</sup>. Interaction of a RNA with RNA-binding proteins (RBP) or microRNA-containing RNA-Induced Silencing Complex (RISC) determines the fate of the transcript, including pre-mRNA splicing, and mRNA stability, localization and translation<sup>[96-102]</sup>. Some of these interactions have been linked to key cellular functions like synaptic plasticity and carcinogenesis<sup>[97-99]</sup>. Cross-linked immunoprecipitation (CLIP) methods coupled to HTS have helped to elucidate the networks of interaction of RNAs with RNA-binding factors<sup>[96-102]</sup>. This analysis has led to a better understanding of RNA biology. For example,

HTS of RNAs interacting with the RBPs Nova<sup>[96]</sup> or HuR<sup>[100-102]</sup> led to the discovery of roles played by these RBPs in the splicing of their target mRNAs. CLIP of Argonaute complexes revealed how the RISC interacts with its target mRNAs and microRNAs and further illuminated microRNA mediated mRNA regulation<sup>[98,99]</sup>. Similarly, CLIP of ribosomes gives us a global view of different aspects of translation (the decoding of mRNA to synthesize protein) as it happens in the cell, including initiation rates, initiation and termination sites<sup>[103]</sup>. Coupling microRNA or RBP modulation to ribosome CLIP or nascent RNA/protein translation assays and HTS can determine the role of these factors in the stability or translation of their target mRNAs<sup>[104]</sup>. Some of the long standing questions of basic biology and medicine are now being tackled with these methodologies<sup>[105]</sup>.

Some examples of current clinical use of these technologies include the use of high-throughput sequencing in colon cancer to study microsatellite instability and its relationship to chemotherapy resistance in colon cancer patients<sup>[106]</sup>. In this study, colon cancer cell lines were compared to normal colonic mucosa. The expression levels of over 40 proteins involved with chemoresistance, DNA repair, DNA damage and drug metabolism were studied. A significant difference in expression of these proteins was noted between the two cell types. In triple negative breast cancer patients, molecular profiling of breast cancer patients in genome-wide analysis is being used to show heterogeneity among this group of patients. By understanding these differences, it allows us an opportunity to identify novel prognostic and predictive biomarkers in an effort to develop novel therapeutic agents<sup>[107]</sup> and will better help us tailor our therapeutic options with individual patient differences. These advances will inevitably become a common part of the treatment algorithms available to our patients with cancer in the near future.

## CONCLUSION

This is an exciting time for many technologies and our understanding of molecular events is increasing each day. As this knowledge base is developed, many techniques that appear to be solely in the realm of the laboratory are becoming commonplace in the care of our surgical cancer patients. These technologies will allow us to better match the molecular makeup of individual patients with the diseases that they suffer from. Promising collaborations among bench scientists, computational biologists and clinicians have been forged in the quest to answer these pressing questions.

## REFERENCES

- 1 **Pantel K**, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. *Nat Rev Cancer* 2008; **8**: 329-340
- 2 **Pantel K**, Alix-Panabières C, Riethdorf S. Cancer micrometastases. *Nat Rev Clin Oncol* 2009; **6**: 339-351
- 3 **Fidler IJ**. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nat Rev Cancer* 2003; **3**: 453-458
- 4 **Cristofanilli M**, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. *J Clin Oncol* 2005; **23**: 1420-1430
- 5 **Alunni-Fabbroni M**, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. *Methods* 2010; **50**: 289-297
- 6 **Clare SE**, Sener SF, Wilkens W, Goldschmidt R, Merkel D, Winchester DJ. Prognostic significance of occult lymph node metastases in node-negative breast cancer. *Ann Surg Oncol* 1997; **4**: 447-451
- 7 **Braun S**, Pantel K, Müller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. *N Engl J Med* 2000; **342**: 525-533
- 8 **Vona G**, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Bréchet C, Paterlini-Bréchet P. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulating tumor cells. *Am J Pathol* 2000; **156**: 57-63
- 9 **Zheng S**, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, Tai YC. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. *J Chromatogr A* 2007; **1162**: 154-161
- 10 **Zach O**, Lutz D. Tumor cell detection in peripheral blood and bone marrow. *Curr Opin Oncol* 2006; **18**: 48-56
- 11 **Gertler R**, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. *Recent Results Cancer Res* 2003; **162**: 149-155
- 12 **Müller V**, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Jänicke F, Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. *Clin Cancer Res* 2005; **11**: 3678-3685
- 13 **Naume B**, Borgen E, Tøssvik S, Pavlak N, Oates D, Nesland JM. Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method. *Cytotherapy* 2004; **6**: 244-252
- 14 **Hayes GM**, Busch R, Voogt J, Siah IM, Gee TA, Hellerstein MK, Chiorazzi N, Rai KR, Murphy EJ. Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. *Leuk Res* 2010; **34**: 809-815
- 15 **Neurauter AA**, Bonyhadi M, Lien E, Nøkleby L, Ruud E, Camacho S, Aarvak T. Cell isolation and expansion using Dynabeads. *Adv Biochem Eng Biotechnol* 2007; **106**: 41-73
- 16 **McNiece I**, Briddell R, Stoney G, Kern B, Zilm K, Recktenwald D, Miltenyi S. Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. *J Hematother* 1997; **6**: 5-11
- 17 **Peters CE**, Woodside SM, Eaves AC. Isolation of subsets of immune cells. *Methods Mol Biol* 2005; **302**: 95-116
- 18 **Allard WJ**, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res* 2004; **10**: 6897-6904
- 19 **Jung R**, Petersen K, Krüger W, Wolf M, Wagener C, Zander A, Neumaier M. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. *Br J Cancer* 1999; **81**: 870-873
- 20 **Smith BM**, Slade MJ, English J, Graham H, Lüchtenborg M,

- Sinnett HD, Cross NC, Coombes RC. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. *J Clin Oncol* 2000; **18**: 1432-1439
- 21 **Xenidis N**, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulas V, Mavroudis D. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. *J Clin Oncol* 2006; **24**: 3756-3762
- 22 **Stathopoulou A**, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamou N, Georgoulas V, Lianidou ES. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. *Int J Cancer* 2006; **119**: 1654-1659
- 23 **Nolan T**, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. *Nat Protoc* 2006; **1**: 1559-1582
- 24 **Fehm T**, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. *Cancer* 2006; **107**: 885-892
- 25 **Borgen E**, Pantel K, Schlimok G, Müller P, Otte M, Renolen A, Ehnle S, Coith C, Nesland JM, Naume B. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. *Cytometry B Clin Cytom* 2006; **70**: 400-409
- 26 **Hsieh HB**, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N, Kuhn P, Bruce RH, Nieva J. High speed detection of circulating tumor cells. *Biosens Bioelectron* 2006; **21**: 1893-1899
- 27 **Krivacic RT**, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, Kepros JF, Barbera T, Ho MY, Chen LB, Lerner RA, Bruce RH. A rare-cell detector for cancer. *Proc Natl Acad Sci USA* 2004; **101**: 10501-10504
- 28 **Somlo G**, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. *Breast Cancer Res Treat* 2011; **128**: 155-163
- 29 **Pachmann K**, Dengler R, Lobodasch K, Fröhlich F, Kroll T, Rengsberger M, Schubert R, Pachmann U. An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer. *J Cancer Res Clin Oncol* 2008; **134**: 59-65
- 30 **Pachmann K**, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, Höffken K. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. *Clin Chem Lab Med* 2005; **43**: 617-627
- 31 **Cruz I**, Ciudad J, Cruz JJ, Ramos M, Gómez-Alonso A, Adansa JC, Rodríguez C, Orfao A. Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. *Am J Clin Pathol* 2005; **123**: 66-74
- 32 **Deng G**, Herrler M, Burgess D, Manna E, Krag D, Burke JF. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. *Breast Cancer Res* 2008; **10**: R69
- 33 **Hayes DF**, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. *Clin Cancer Res* 2006; **12**: 4218-4224
- 34 **Shaffer DR**, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. *Clin Cancer Res* 2007; **13**: 2023-2029
- 35 **Nagrath S**, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature* 2007; **450**: 1235-1239
- 36 **Pachmann K**, Camara O, Kavallaris A, Krauspe S, Malariski N, Gajda M, Kroll T, Jörke C, Hammer U, Altendorf-Hofmann A, Rabenstein C, Pachmann U, Runnebaum I, Höffken K. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. *J Clin Oncol* 2008; **26**: 1208-1215
- 37 **Xu T**, Lu B, Tai YC, Goldkorn A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. *Cancer Res* 2010; **70**: 6420-6426
- 38 **Botteri E**, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. *Breast Cancer Res Treat* 2010; **122**: 211-217
- 39 **Paterlini-Brechot P**, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. *Cancer Lett* 2007; **253**: 180-204
- 40 **Cohen SJ**, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 3213-3221
- 41 **Allen JE**, El-Deiry WS. Circulating Tumor Cells and Colorectal Cancer. *Curr Colorectal Cancer Rep* 2010; **6**: 212-220
- 42 **Schena M**, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. *Science* 1995; **270**: 467-470
- 43 **DeRisi J**, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM. Use of a cDNA microarray to analyse gene expression patterns in human cancer. *Nat Genet* 1996; **14**: 457-460
- 44 **Khan J**, Bittner ML, Chen Y, Meltzer PS, Trent JM. DNA microarray technology: the anticipated impact on the study of human disease. *Biochim Biophys Acta* 1999; **1423**: M17-M28
- 45 **Khan J**, Saal LH, Bittner ML, Chen Y, Trent JM, Meltzer PS. Expression profiling in cancer using cDNA microarrays. *Electrophoresis* 1999; **20**: 223-229
- 46 **Albertson DG**. Profiling breast cancer by array CGH. *Breast Cancer Res Treat* 2003; **78**: 289-298
- 47 **Ruano Y**, Mollejo M, de Lope AR, Hernández-Moneo JL, Martínez P, Meléndez B. Microarray-based comparative genomic hybridization (array-CGH) as a useful tool for identifying genes involved in Glioblastoma (GB). *Methods Mol Biol* 2010; **653**: 35-45
- 48 **Al-Mulla F**. Microarray-based CGH and copy number analysis of FFPE samples. *Methods Mol Biol* 2011; **724**: 131-145
- 49 **Sager R**. Expression genetics in cancer: shifting the focus from DNA to RNA. *Proc Natl Acad Sci USA* 1997; **94**: 952-955
- 50 **Flach J**, Dicker F, Schnittger S, Schindela S, Kohlmann A, Haferlach T, Kern W, Haferlach C. An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38

- paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. *Leukemia* 2011; **25**: 713-718
- 51 **Ntzani EE**, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. *Lancet* 2003; **362**: 1439-1444
- 52 **Arango D**, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R, Nicorici D, Hautaniemi S, Alazzouzi H, Mecklin JP, Järvinen H, Hemminki A, Astola J, Schwartz S, Aaltonen LA. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. *Gastroenterology* 2005; **129**: 874-884
- 53 **Lin YH**, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, Phillips V, Thompson-Fawcett M, Kasabov N, Toro T, Merrie AE, van Rij A, Yoon HS, McCall JL, Siewert JR, Holzmann B, Reeve AE. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. *Clin Cancer Res* 2007; **13**: 498-507
- 54 **Alizadeh AA**, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JJ, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 2000; **403**: 503-511
- 55 **Sadi AM**, Wang DY, Youngson BJ, Miller N, Boerner S, Done SJ, Leong WL. Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens. *BMC Cancer* 2011; **11**: 253: 1-25313
- 56 **Graham LD**, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, Vizgoff EK, Dunne R, Pimlott L, Young GP, Lapointe LC, Molloy PL. Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. *Genes Cancer* 2011; **2**: 829-840
- 57 **Zanivan S**, Gnad F, Wickström SA, Geiger T, Macek B, Cox J, Fässler R, Mann M. Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. *J Proteome Res* 2008; **7**: 5314-5326
- 58 **Ocak S**, Chaurand P, Massion PP. Mass spectrometry-based proteomic profiling of lung cancer. *Proc Am Thorac Soc* 2009; **6**: 159-170
- 59 **Bañez LL**, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, McLeod DG, Moul JW, Srivastava S. Diagnostic potential of serum proteomic patterns in prostate cancer. *J Urol* 2003; **170**: 442-446
- 60 **Huang YJ**, Xuan C, Zhang BB, Liao M, Deng KF, He M, Zhao JM. SELDI-TOF MS profiling of serum for detection of nasopharyngeal carcinoma. *J Exp Clin Cancer Res* 2009; **28**: 85
- 61 **Han KQ**, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. *Am J Clin Oncol* 2008; **31**: 133-139
- 62 **Lim JY**, Cho JY, Paik YH, Chang YS, Kim HG. Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. *Int J Biol Markers* 2007; **22**: 281-286
- 63 **Wu SP**, Lin YW, Lai HC, Chu TY, Kuo YL, Liu HS. SELDI-TOF MS profiling of plasma proteins in ovarian cancer. *Taiwan J Obstet Gynecol* 2006; **45**: 26-32
- 64 **Bons JA**, Wodzig WK, van Diejen-Visser MP. Protein profiling as a diagnostic tool in clinical chemistry: a review. *Clin Chem Lab Med* 2005; **43**: 1281-1290
- 65 **Zhou G**, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF, Zhao Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. *Mol Cell Proteomics* 2002; **1**: 117-124
- 66 **Geiger T**, Cox J, Ostasiewicz P, Wisniewski JR, Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. *Nat Methods* 2010; **7**: 383-385
- 67 **Lee KK**, Todorova K, Mandinova A. Maximizing early detection of esophageal squamous cell carcinoma via SILAC-proteomics. *Cancer Biol Ther* 2010; **10**: 811-813
- 68 **Kashyap MK**, Harsha HC, Renuse S, Pawar H, Sahasrabudhe NA, Kim MS, Marimuthu A, Keerthikumar S, Muthusamy B, Kandasamy K, Subbannayya Y, Prasad TS, Mahmood R, Chaerkady R, Meltzer SJ, Kumar RV, Rustgi AK, Pandey A. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. *Cancer Biol Ther* 2010; **10**: 796-810
- 69 **Yocum AK**, Busch CM, Felix CA, Blair IA. Proteomics-based strategy to identify biomarkers and pharmacological targets in leukemias with t(4; 11) translocations. *J Proteome Res* 2006; **5**: 2743-2753
- 70 **Yang W**, Cai Q, Lui VW, Everley PA, Kim J, Bholra N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. *J Proteome Res* 2010; **9**: 3073-3082
- 71 **Imami K**, Sugiyama N, Tomita M, Ishihama Y. Quantitative proteome and phosphoproteome analyses of cultured cells based on SILAC labeling without requirement of serum dialysis. *Mol Biosyst* 2010; **6**: 594-602
- 72 **Doucet A**, Butler GS, Rodríguez D, Prudova A, Overall CM. Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. *Mol Cell Proteomics* 2008; **7**: 1925-1951
- 73 **Haab BB**. Antibody arrays in cancer research. *Mol Cell Proteomics* 2005; **4**: 377-383
- 74 **Haab BB**. Methods and applications of antibody microarrays in cancer research. *Proteomics* 2003; **3**: 2116-2122
- 75 **Scholler N**, Crawford M, Sato A, Drescher CW, O'Brian KC, Kiviat N, Anderson GL, Urban N. Bead-based ELISA for validation of ovarian cancer early detection markers. *Clin Cancer Res* 2006; **12**: 2117-2124
- 76 **Zangar RC**, Varnum SM, Covington CY, Smith RD. A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays. *Dis Markers* 2004; **20**: 135-148
- 77 **Hawkins RD**, Hon GC, Ren B. Next-generation genomics: an integrative approach. *Nat Rev Genet* 2010; **11**: 476-486
- 78 **Ng SB**, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, Shaffer T, Wong M, Bhattacharjee A, Eichler EE, Bamshad M, Nickerson DA, Shendure J. Targeted capture and massively parallel sequencing of 12 human exomes. *Nature* 2009; **461**: 272-276
- 79 **Bevilacqua L**, Doly S, Kaprio J, Yuan Q, Tikkanen R, Paunio T, Zhou Z, Wedenoja J, Maroteaux L, Diaz S, Belmer A, Hodgkinson CA, Dell'osso L, Suvisaari J, Coccaro E, Rose RJ, Peltonen L, Virkkunen M, Goldman D. A population-specific HTR2B stop codon predisposes to severe impulsivity. *Nature* 2010; **468**: 1061-1066
- 80 **Alkan C**, Kidd JM, Marques-Bonet T, Aksay G, Antonacci F, Hormozdiari F, Kitzman JO, Baker C, Malig M, Mutlu O, Sahinalp SC, Gibbs RA, Eichler EE. Personalized copy number and segmental duplication maps using next-generation sequencing. *Nat Genet* 2009; **41**: 1061-1067
- 81 **Wang Z**, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* 2009; **10**: 57-63
- 82 **Maher CA**, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM. Transcriptome sequencing to detect gene fusions in cancer. *Nature* 2009; **458**: 97-101
- 83 **Sultan M**, Schulz MH, Richard H, Magen A, Klingenhoff A, Scherf M, Seifert M, Borodina T, Soldatov A, Parkhomchuk

- D, Schmidt D, O'Keefe S, Haas S, Vingron M, Lehrach H, Yaspo ML. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. *Science* 2008; **321**: 956-960
- 84 **Core LJ**, Waterfall JJ, Lis JT. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. *Science* 2008; **322**: 1845-1848
- 85 **Farazi TA**, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, Brown M, Hafner M, Reyat F, van Kouwenhove M, Kreike B, Sie D, Hovestadt V, Wessels LF, van de Vijver MJ, Tuschl T. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. *Cancer Res* 2011; **71**: 4443-4453
- 86 **Bernstein BE**, Meissner A, Lander ES. The mammalian epigenome. *Cell* 2007; **128**: 669-681
- 87 **Jones PA**, Baylin SB. The epigenomics of cancer. *Cell* 2007; **128**: 683-692
- 88 **Lister R**, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, Ren B, Ecker JR. Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* 2009; **462**: 315-322
- 89 **Barski A**, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. *Cell* 2007; **129**: 823-837
- 90 **Wang Z**, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. Combinatorial patterns of histone acetylations and methylations in the human genome. *Nat Genet* 2008; **40**: 897-903
- 91 **Boyle AP**, Davis S, Shulha HP, Meltzer P, Margulies EH, Weng Z, Furey TS, Crawford GE. High-resolution mapping and characterization of open chromatin across the genome. *Cell* 2008; **132**: 311-322
- 92 **Palomero T**, Ferrando AA. Genomic tools for dissecting oncogenic transcriptional networks in human leukemia. *Leukemia* 2009; **23**: 1236-1242
- 93 **Sun H**, Wu J, Wickramasinghe P, Pal S, Gupta R, Bhattacharyya A, Agosto-Perez FJ, Showe LC, Huang TH, Davuluri RV. Genome-wide mapping of RNA Pol-II promoter usage in mouse tissues by ChIP-seq. *Nucleic Acids Res* 2011; **39**: 190-201
- 94 **Welboren WJ**, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. *EMBO J* 2009; **28**: 1418-1428
- 95 **Fullwood MJ**, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, Lee YK, Karuturi RK, Herve T, Bourque G, Stunnenberg HG, Ruan X, Cacheux-Rataboul V, Sung WK, Liu ET, Wei CL, Cheung E, Ruan Y. An oestrogen-receptor-alpha-bound human chromatin interactome. *Nature* 2009; **462**: 58-64
- 96 **Ule J**, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. CLIP identifies Nova-regulated RNA networks in the brain. *Science* 2003; **302**: 1212-1215
- 97 **Darnell JC**, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* 2011; **146**: 247-261
- 98 **Chi SW**, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. *Nature* 2009; **460**: 479-486
- 99 **Hafner M**, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M, Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. *Cell* 2010; **141**: 129-141
- 100 **Lebedeva S**, Jens M, Theil K, Schwanhäusser B, Selbach M, Landthaler M, Rajewsky N. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. *Mol Cell* 2011; **43**: 340-352
- 101 **Mukherjee N**, Corcoran DL, Nusbaum JD, Reid DW, Georgiev S, Hafner M, Ascano M, Tuschl T, Ohler U, Keene JD. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. *Mol Cell* 2011; **43**: 327-339
- 102 **Srikantan S**, Gorospe M. UneCLIPsing HuR nuclear function. *Mol Cell* 2011; **43**: 319-321
- 103 **Ingolia NT**, Ghaemmaghami S, Newman JR, Weissman JS. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. *Science* 2009; **324**: 218-223
- 104 **Guo H**, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature* 2010; **466**: 835-840
- 105 **Park PJ**. ChIP-seq: advantages and challenges of a maturing technology. *Nat Rev Genet* 2009; **10**: 669-680
- 106 **Duldulao MP**, Lee W, Le M, Chen Z, Li W, Wang J, Gao H, Li H, Kim J, Garcia-Aguilar J. Gene expression variations in microsatellite stable and unstable colon cancer cells. *J Surg Res* 2012; **174**: 1-6
- 107 **Ma CX**, Luo J, Ellis MJ. Molecular profiling of triple negative breast cancer. *Breast Dis* 2010; **32**: 73-84

S- Editor Jiang L L- Editor Roemmele A E- Editor Li JY

## Acknowledgments to reviewers of World Journal of Surgical Procedures

We acknowledge our sincere thanks to our reviewers. Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of our World Series Journals. Both the editors of the journals and authors of the manuscripts submitted to the journals are grateful to the following reviewers for reviewing the articles (either published or rejected) over the past period of time.

**Konstantinos P Economopoulos, MD**, Research Fellow in Surgery, Department of General Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA 02114, United States

**Steven N Hochwald, MD, Chief, Associate Professor** of Surgery, Edward M Copeland, III Professor of Surgical Oncology, Molecular Genetics and Microbiology, Division of Surgical Oncology, University of Florida College of Medicine, 1600 SW Archer Road, Room 6165, PO Box 100109, Gainesville, FL 32610, United States

**Juan Viñas Salas, Professor** of Surgery, Department of Surgery, Arnau de Vilanova University Hospital, Alcalde Rovira Roure 80, 25198 Lleida, Spain

## Events Calendar 2012

January 3-9, 2012

The 9th International Conference on Cholesteatoma and Ear Surgery  
Nagasaki, Japan

January 7-9, 2012

Vascular Annual Meeting  
Washington, DC, United States

January 13-15, 2012

Vattikuti Global Robotics 2012-A  
Mutispecialty Robotic Surgery  
Conference  
New Delhi, India

January 14-17, 2012

Arthroscopic Surgery 2012  
Scottsdale, AZ, United States

January 23-26, 2012

11th Middle East Surgery  
Conference  
Dubai, United Arab Emirates

February 9-12, 2012

8th Tremblant Vascular Surgery  
Meeting 2012  
Québec, Canada

February 14-16, 2012

7th Annual Academic Surgical  
Conference  
Las Vegas, NV, United States

February 16-19, 2012

10th Biennial National Congress of IAGES workshop on minimal Access Surgery  
Ahmedabad, India

March, 2012

8th International Congress of Update in Cardiology and Cardiovascular Surgery  
Antalya, Turkey

March 9-11, 2012

International Society For Vascular Surgery Congress  
Florida, FL, United States

March 14-17, 2012

Society For Clinical Vascular Surgery  
40th Annual Symposium 2012  
Las Vegas, NV, United States

July, 2012

8th International Conference on Head and Neck Cancer  
Toronto, Canada

September, 2012

32nd Congress of the European Society of Surgical Oncology  
Valencia, Spain

October 26-30, 2012

ASPS Plastic Surgery 2012  
Conference - The American Society of Plastic Surgeons - New Orleans  
New Orleans, LA, United States

**GENERAL INFORMATION**

*World Journal of Surgical Procedures* (*World J Surg Proced*, *WJSP*, online ISSN 2219-2832, DOI: 10.5412) is a bimonthly peer-reviewed, online, open-access (OA), journal supported by an editorial board consisting of 106 experts in surgical procedures from 23 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

**Maximization of personal benefits**

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJSP* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJSP* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJSP* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality ar-

ticles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

**Aims and scope**

*WJSP* aims to rapidly report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of surgical procedures. *WJSP* covers ambulatory surgical procedures, cardiovascular surgical procedures, digestive system surgical procedures, endocrine surgical procedures, obstetric surgical procedures, neurosurgical procedures, ophthalmologic surgical procedures, oral surgical procedures, orthopedic procedures, otorhinolaryngologic surgical procedures, reconstructive surgical procedures, thoracic surgical procedures, urogenital surgical procedures, computer-assisted surgical procedures, elective surgical procedures, and minimally invasive, surgical procedures, specifically including ablation techniques, anastomosis, assisted circulation, bariatric surgery, biopsy, body modification, non-therapeutic, curettage, debridement, decompression, deep brain stimulation, device removal, dissection, drainage, electrosurgery, extracorporeal circulation, hemostasis, intraoperative care, laparotomy, ligation, lymph node excision, mastectomy, microsurgery, monitoring, intraoperative, ostomy, paracentesis, pelvic exenteration, perioperative care, postoperative care, preoperative care, prosthesis implantation, reoperation, second-look surgery, splenectomy, suture techniques, symphysiotomy, tissue and organ harvesting, transplantation, diagnostic imaging, endoscopy, traditional medicine, integrated Chinese and Western medicine, evidence-based medicine and epidemiology. The journal also publishes original articles and reviews that report the results of applied and basic research in fields related to surgical procedures, such as immunology, physiopathology, cell biology, pharmacology, medical genetics, and pharmacology of Chinese herbs.

**Columns**

The columns in the issues of *WJSP* will include: (1) Editorial: To introduce and comment on the substantial advance and its importance in the fast-developing areas; (2) Frontier: To review the most representative achievements and comment on the current research status in the important fields, and propose directions for the future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (6) Review: To systemically review the most representative progress and unsolved problems in the major scientific disciplines, comment on the current research status, and make suggestions on the future work; (7) Original Articles: To originally report the innovative and valuable findings in surgical procedures; (8) Brief Articles: To briefly report the novel and innovative findings in surgical procedures; (9) Case Report: To report a rare or typical case; (10) Letters to the Editor: To discuss and make reply to the contributions published in *WJSP*, or to introduce and comment on a controversial issue of general interest; (11) Book Reviews: To introduce and comment on quality monographs of surgical procedures; and (12) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in surgical procedures.

## Instructions to authors

### Name of journal

World Journal of Surgical Procedures

### ISSN

ISSN 2219-2832 (online)

### Editor-in-Chief

**Massimo Chello, MD, Professor**, Department of Cardiovascular Sciences, University Campus Bio Medico of Rome, Via Alvaro Del Portillo 200, 00128 Rome, Italy

**Feng Wu, MD, PhD, Professor**, Nuffield Department of Surgical Sciences, University of Oxford, Level 6, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU, United Kingdom

### Editorial Office

World Journal of Surgical Procedures

Editorial Department: Room 903, Building D,

Ocean International Center,

No. 62 Dongsihuan Zhonglu,

Chaoyang District, Beijing 100025, China

E-mail: wjisp@wjgnet.com

<http://www.wjgnet.com>

Telephone: +86-10-85381892

Fax: +86-10-85381893

### Indexed and Abstracted in

Digital Object Identifier.

### Published by

Baishideng Publishing Group Co., Limited

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, etc. The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJSP* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of

organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esp/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/2219-2832/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2219-2832/g_info_20100722180909.htm))

before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjsp@wjgnet.com](mailto:wjsp@wjgnet.com), or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJSP*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article.

For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

### Abstract

There are unstructured abstracts (no less than 256 words) and structured abstracts (no less than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no less than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no less than 140 words); RESULTS (no less than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/2219-2832/g\\_info\\_list.htm](http://www.wjgnet.com/2219-2832/g_info_list.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle to publish high resolution-figures for the printed and E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* <

## Instructions to authors

0.05, <sup>b</sup> $P < 0.01$  should be noted ( $P > 0.05$  should not be noted). If there are other series of  $P$  values, <sup>c</sup> $P < 0.05$  and <sup>d</sup> $P < 0.01$  are used. A third series of  $P$  values can be expressed as <sup>e</sup> $P < 0.05$  and <sup>f</sup> $P < 0.01$ . Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

#### In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

#### Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.00000035706.28494.09]

#### Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

#### No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

#### Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

#### Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

#### No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

#### Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

#### Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

#### Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

#### Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

#### Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

#### Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

#### Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

#### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

**Statistical expression**

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as  $\nu$  (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

**Units**

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu\text{g/L}$ ; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23243641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/2220-315x/g\\_info\\_20100725073806.htm](http://www.wjgnet.com/2220-315x/g_info_20100725073806.htm).

**Abbreviations**

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSE, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

**Italics**

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

**Examples for paper writing**

**Editorial:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725071851.htm](http://www.wjgnet.com/2219-2832/g_info_20100725071851.htm)

**Frontier:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725071932.htm](http://www.wjgnet.com/2219-2832/g_info_20100725071932.htm)

**Topic highlight:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725072121.htm](http://www.wjgnet.com/2219-2832/g_info_20100725072121.htm)

**Observation:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725072232.htm](http://www.wjgnet.com/2219-2832/g_info_20100725072232.htm)

**Guidelines for basic research:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725072344.htm](http://www.wjgnet.com/2219-2832/g_info_20100725072344.htm)

**Guidelines for clinical practice:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725072543.htm](http://www.wjgnet.com/2219-2832/g_info_20100725072543.htm)

**Review:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725072656.htm](http://www.wjgnet.com/2219-2832/g_info_20100725072656.htm)

**Original articles:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725072755.htm](http://www.wjgnet.com/2219-2832/g_info_20100725072755.htm)

**Brief articles:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725072920.htm](http://www.wjgnet.com/2219-2832/g_info_20100725072920.htm)

**Case report:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725073015.htm](http://www.wjgnet.com/2219-2832/g_info_20100725073015.htm)

**Letters to the editor:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725073136.htm](http://www.wjgnet.com/2219-2832/g_info_20100725073136.htm)

[http://www.wjgnet.com/2219-2832/g\\_info\\_20100725073214.htm](http://www.wjgnet.com/2219-2832/g_info_20100725073214.htm)

**Book reviews:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725073214.htm](http://www.wjgnet.com/2219-2832/g_info_20100725073214.htm)

**Guidelines:** [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725073300.htm](http://www.wjgnet.com/2219-2832/g_info_20100725073300.htm)

**SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED**

Please revise your article according to the revision policies of *WJSP*. The revised version including manuscript and high-resolution image figures (if any) should be re-submitted online (<http://www.wjgnet.com/esps/>). The author should send the copyright transfer letter, responses to the reviewers, English language Grade B certificate (for non-native speakers of English) and final manuscript checklist to [wjsp@wjgnet.com](mailto:wjsp@wjgnet.com).

**Language evaluation**

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

**Copyright assignment form**

Please download a Copyright assignment form from [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725073726.htm](http://www.wjgnet.com/2219-2832/g_info_20100725073726.htm).

**Responses to reviewers**

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/2219-2832/g\\_info\\_20100725073445.htm](http://www.wjgnet.com/2219-2832/g_info_20100725073445.htm).

**Proof of financial support**

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

**Links to documents related to the manuscript**

*WJSP* will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

**Science news releases**

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

**Publication fee**

*WJSP* is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 600 USD per article. Editorial, topic highlights, original articles, brief articles, book reviews and letters to the editor are published free of charge.